Kazuyo Sasaki Selected Research

3- (4- (4- (3- methyl- 1- phenyl- 1H- pyrazol- 5- yl)piperazin- 1- yl)pyrrolidin- 2- ylcarbonyl)thiazolidine

1/2022	Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan.
1/2020	Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan.
1/2020	Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan.
6/2018	Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance.
6/2018	Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients.
4/2018	Efficacy and Safety of Teneligliptin 40 mg in Type 2 Diabetes: A Pooled Analysis of Two Phase III Clinical Studies.
2/2018	Safety and efficacy of long-term treatment with teneligliptin: Interim analysis of a post-marketing surveillance of more than 10,000 Japanese patients with type 2 diabetes mellitus.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kazuyo Sasaki Research Topics

Disease

8	Type 2 Diabetes Mellitus (MODY) 01/2022 - 01/2015
5	Body Weight (Weight, Body) 01/2022 - 10/2017
3	Diabetes Mellitus 01/2022 - 01/2020
2	Insulin Resistance 01/2020 - 01/2015
2	Hyperglycemia 06/2018 - 02/2018
1	Non-alcoholic Fatty Liver Disease 01/2020
1	Fatty Liver 01/2020
1	Obesity 01/2020
1	Glucose Intolerance 01/2020
1	Diabetes Complications 06/2018
1	Drug-Related Side Effects and Adverse Reactions 06/2018
1	Chronic Renal Insufficiency 06/2018
1	Chronic Kidney Failure (Chronic Renal Failure) 06/2018
1	Polyuria 01/2018
1	Urinary Tract Infections (Urinary Tract Infection) 01/2018
1	Hypoglycemia (Reactive Hypoglycemia) 01/2018

Drug/Important Bio-Agent (IBA)

7	3- (4- (4- (3- methyl- 1- phenyl- 1H- pyrazol- 5- yl)piperazin- 1- yl)pyrrolidin- 2- ylcarbonyl)thiazolidineIBA 01/2022 - 02/2018
5	CanagliflozinIBA 01/2022 - 10/2017
3	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2022 - 01/2018
2	Sodium-Glucose Transport ProteinsIBA 01/2022 - 01/2020
2	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 06/2018
1	TabletsIBA 01/2022
1	Aluminum Oxide (Sapphire)IBA 01/2022
1	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2022
1	Blood Glucose (Blood Sugar)IBA 01/2020
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2018
1	KetonesIBA 01/2018
1	Glucagon-Like Peptide 1 (GLP 1)IBA 10/2017
1	IncretinsIBA 10/2017
1	Insulin (Novolin)FDA Link 01/2015

Therapy/Procedure

2	Glycemic Control 06/2018 - 01/2015
1	Therapeutics 01/2018